Equity Overview
Price & Market Data
Price: $0.989
Daily Change: -$0.0209 / 2.11%
Range: $0.86 - $1.01
Market Cap: $36,912,248
Volume: 71,439
Performance Metrics
1 Week: -2.94%
1 Month: -2.94%
3 Months: -28.26%
6 Months: -1.00%
1 Year: -17.50%
YTD: -23.26%
Company Details
Employees: 10
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.